SOAT-2/ACAT-2 Polyclonal Antibody

Sterol O-acyltransferase 2 (SOAT-2), also known as acyl-coenzyme A:cholesterol acyltransferase-2 (ACAT-2), is an enzyme encoded by ACAT2 in humans that catalyzes the intracellular formation of cholesterol esters from cholesterol and long-chain fatty acyl-coenzyme A.¹ It is constitutively expressed in the liver and small intestine and localized to the rough endoplasmic reticulum where it preferentially utilizes oleic acid (Item Nos. 90260 | 24659) or palmitic acid (Item No. 10006627) as fatty acid substrates for the synthesis of cholesterol esters, which are stored intracellularly or packaged into chylomicrons or VLDL and secreted into the blood stream. SOAT-2/ACAT-2 protein levels are increased in macrophages under various pathological conditions, including atherosclerosis.² SOAT-2/ACAT-2 activity and protein levels are increased by cholesterol in vitro and in vivo, and ACAT2 expression is increased by the transcription factors hepatocyte nuclear factor 1-α (HNF-1-α) and HNF-4-α in Caco-2 cells and human liver, respectively.¹ Genome-wide deletion of Acat2 reduces intestinal cholesterol absorption and decreases hepatic, but not plasma, total cholesterol levels in mice fed a high-cholesterol diet.³ Liver ACAT2 activity is negatively correlated with plasma HDL-C and ApoA1 in normolipidemic patients.⁴ Cayman's SOAT-2/ACAT-2 Polyclonal Antibody can be used for immunofluorescence (IF), immunohistochemistry (IHC), and Western blot (WB) applications. The antibody recognizes the N-terminal region of SOAT-2/ACAT-2 at approximately 60 kDa from human, mouse, ovine, porcine, and rat samples.

WARNING This product is not for human or veterinary use.

1. Pramfalk, C., Eriksson, M., and Parini, P. Cholesteryl esters and ACAT. Eur. J. Lipid Sci. Technol. 114(6), 624-633 (2012).

2. Sakashita, N., Miyazaki, A., Chang, C.C.Y., et al. Acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) is induced in monocyte-derived macrophages: In vivo and in vitro studies. Lab. Invest. 83(11), 1569-1581 (2003).

3. Repa, J.J., Buhman, K.K., Farese, R.V., Jr., et al. ACAT2 deficiency limits cholesterol absorption in the cholesterol-fed mouse: impact on hepatic cholesterol homeostasis. Hepatology 40(5), 1088-1097 (2004).

4. Parini, P., Jiang, Z.-Y., Einarsson, C., et al. ACAT2 and human hepatic cholesterol metabolism: identification of important gender-related differences in normolipidemic, non-obese Chinese patients. Atherosclerosis 207(1), 266-271 (2009).

Grenier, E., Garofalo, C., Delvin, E., et al. Modulatory role of PYY in transport and metabolism of cholesterol in intestinal epithelial cells. Plos One 7(7), e40992 (2012).

Ikenoya, M., Yoshinaka, Y., Kobayashi, H., et al. A selective ACAT-1 inhibitor, K^-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels. Atherosclerosis 191(2), 290-297 (2007).